JAMA Network Home
Sign In
Original Investigation

Pathologic Response After Neoadjuvant Chemoimmunotherapy in Head and Neck Squamous Cell Carcinoma

JAMA Otolaryngology–Head & Neck Surgery 10.1001/jamaoto.2026.2259

August 13, 2026 at 11:00 AM EDT

Read the full article

In this cohort study, neoadjuvant chemoimmunotherapy was associated with substantially higher rates of pCR and MPR compared with immunotherapy alone in resectable HNSCC. These findings support the potential role of combination regimens in improving tumor response, although prospective trials are needed to determine effects on survival.

Corresponding Author: Scott A. Roof, MD (scott.roof@mountsinai.org), and Ethan A. Gomez, BS (ethan.gomez@icahn.mssm.edu), Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl, New York, NY 10029

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2026.2259?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081326

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks